Eyevensys, a private biotechnology company, has received approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to advance its technology, EyeCET platform into clinical development.
The EyeCET platform uses Eyevensys' proprietary electro-transfection injection system (ETIS) to deliver plasmids that encode for the production of disease-specific therapeutic proteins in the ciliary muscle of the eye. Eyevensys' lead product, EYS606 uses a plasmid encoding for the production of anti-TNFa for the treatment of Non-infectious Uveitis (NIU). EYS606 has been granted an orphan drug designation by the EMA for the treatment of NIU.
Raffy Kazandjian, CEO of Eyevensys, said: "We are pleased the MHRA has approved our unique technology to enter into clinical development in the UK. This validation is another commitment of EYS606 alongside the ANSM approval. We are now all set up to demonstrate that our technology can provide much better outcomes for patients with ophthalmology diseases that need improved treatment options."
Eyevensys is a private biotechnology company developing its innovative EyeCET platform to enable the sustained intraocular production of therapeutic proteins to treat a broad range of ophthalmic diseases.